Dean Y. Li

Stories

Merck's remigromig meets main goal in pivotal eye disease trial

Overseeing remigromig's development and regulatory path

Merck said Thursday its experimental eye drug remigromig hit the primary endpoint in a 984-patient trial for diabetic macular edema. Both tested doses matched ranibizumab, the long-standing standard, on visual acuity at 52 weeks.

Updated Sep 24

FDA approves first oral PCSK9 inhibitor for high cholesterol

New Capabilities

Led the program behind Merck's first-in-class approval

For a decade, the most powerful cholesterol drugs came only as shots. On July 16, 2026, the FDA approved Merck's Lipfendra, a once-daily pill that cut LDL cholesterol about as much as those injections did.

Updated Jul 16

The first personalized cancer vaccine reaches pivotal testing

New Capabilities

Overseeing Merck's post-Keytruda pipeline strategy

Cancer vaccines have promised to train the immune system against tumors for decades. None has delivered a durable, replicable benefit until now.

Updated May 22

Notable Quotes

30% to 40% of people don't respond or stop responding to existing VEGF drugs.

from Merck's remigromig meets main goal in pivotal eye disease trial · Updated Sep 24

Merck framed the pill as a way to reach patients who never started, or stopped, injectable cholesterol therapy.

from FDA approves first oral PCSK9 inhibitor for high cholesterol · Updated Jul 16